Lubiprostone: Treatment of constipation treatment of irritable bowel syndrome treatment of postoperative ileus CIC-2 channel activator

Drugs of the Future

Volumn 29, Issue 4, 2004, Pages 336-341

  Sorbera, L A ^a   Castaner J ^a   Mealy, N E ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE BROMIDE; ABT 224; ALVIMOPAN; ANTIDEPRESSANT AGENT; BULKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORIDE CHANNEL; CHLORIDE CHANNEL ACTIVATING AGENT; DICHLOROMETHANE; DIMETHYL SULFOXIDE; FATTY ACID DERIVATIVE; GASTROINTESTINAL AGENT; KETONE DERIVATIVE; LACTONE; LAXATIVE; LUBIPROSTONE; LUBRICATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OPIATE ANTAGONIST; PHOSPHONIC ACID DERIVATIVE; PLACEBO; POTASSIUM; PROSTAGLANDIN E1 DERIVATIVE; SEROTONIN 4 AGONIST; SODIUM; TEGASEROD; THALLIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISICOL; WATER;

BASOLATERAL MEMBRANE; CHANNEL GATING; CHEMICAL REACTION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONSTIPATION; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; FLATULENCE; FOLLOW UP; HEADACHE; HUMAN; ILEUS; INCIDENCE; INTESTINE FLUID; INTESTINE SECRETION; IRRITABLE COLON; KINESIOTHERAPY; LIFESTYLE; NAUSEA; NONHUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; REVIEW; TREATMENT FAILURE;

EID: 2642517752     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.04.793861     Document Type: Review

References (18)

1. Ueno, R. (R-Tech Ueno, Ltd.). Promotion of wound-healing with 15-keto-prostaglandin cpds. EP 0503887, US 5252605.
2. Ueno, R. (R-Tech Ueno, Ltd.). Endothelin antagonist. EP 0978284, US 6197821, WO 9927934.
3. Ueno, R., Ueno, R., Kato, I., Oda, T. (Ueno Fine Chemicals Industry, Ltd.). Prostaglandins E and anti-ulcers containing same. EP 0284180, JP 1989052753, US 5166174, US 5225439, US 5284858, US 5380709, US 5428062, US 5886034, US 6265440.
4. Ueno, R. (Sucampo Pharma AG). Anti-constipation compsn. CA 2419741, EP 1315485, US 6414016, WO 0220007.
5. Ueno, R., Habe, T. (R-Tech Ueno, Ltd.). Novel compsn. and method for stabilizing the same. CA 2385732, EP 1220849, US 6583174, WO 0127099.
6. Velio, P., Bassotti, G. Chronic idiopathic constipation: Pathophysiology and treatment. J Clin Gastroenterol 1996, 22: 190-6.
7. Whitehead, W.E., Chaussade, S., Corazziari, E., Kumar, D. Report of an international workshop on management of constipation. Gastroenterol Int 1991, 4: 99-113.
8. Thompson, W.G., Creed, F., Drossman, D.A. et al. Functional bowel disorders and chronic functional abdominal pain. Gastroenterol Int 1992, 5: 75-91.
9. Prous Science Drug R&D Backgrounders: Irritable bowel syndrome (online publication). Updated March 24, 2004.
10. Cuppoletti, J., Malinowska, D.H., Tewari, K.P., Sherry, A.M., Patchen, M.L., Ueno, R. Recombinant and native intestinal cell CIC-2 Cl-channels are activated by RU-0211. Dig Dis Week (May 19-22, San Francisco) 2002, Abst W955.
11. Ueno, R., Cuppoletti, J. (Sucampo Pharma AG). Prostaglandin analogs as chloride channel opener. US 2003130352, WO 0330912.
12. Ueno, R., Patchen, M.L. (Sucampo Pharma AG). Dosage unit comprising a prostaglandin analog for treating constipation. US 2003119898, WO 0341716.
13. Johanson, J.F., Gargano, M.A., Patchen, M.L., Ueno, R. Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation. Dig Dis Week (May 19-22, San Francisco) 2002, Abst M1511.
14. Johanson, J.F., Gargano, M.A., Holland, P.C., Patchen, M.L., Ueno, R. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Dig Dis Week (May 17-22, Orlando) 2003, Abst 372.
15. Sucampo completes first open-label safety study for treatment of constipation with proprietary agent SPI-0211. Sucampo Pharmaceuticals Press Release September 15, 2003.
16. Sucampo completes second phase III pivotal efficacy study for treatment of constipation with proprietary agent SPI-0211. Sucampo Pharmaceuticals Press Release January 12, 2004.
17. Second phase III safety study of SPI-0211 confirms earlier positive results. DailyDrugNews.com (Daily Essentials) February 23, 2004.
18. Enrollment completed in phase II study of SPI-0211 for IBS. DailyDrugNews.com (Daily Essentials) March 25, 2004.